Tjalf Ziemssen
Tjalf Ziemssen, MD is an expert in Neurology at University Hospital Carl Gustav Carus (Germany). As of October 2026, ScienceLeadR ranks Tjalf Ziemssen in the top 1% of experts worldwide for Secondary Progressive Multiple Sclerosis, Multiple Sclerosis and Autoimmune Diseases. Tjalf Ziemssen has authored 739 publications, the most recent in 2026, and is an investigator in 35 clinical trials, 9 of them ongoing. SLR score: 3,089 (community average: 125). How the SLR is computed.
LeadR Profile
Neurology
Subspecialties: Immunology - Internal Medicine - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1998 - 2026
Number : 739
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| User-centered design and formative evaluation of a gait dashboard for multidimensional walking assessment in multiple sclerosis. PMID 42774205 — sclerosis, multiple sclerosis, data visualization, gait analysis, communication, workflow, gait, walking, user-centered design, digital health | Front Digit Health | 2026 | 0 |
| Effects of Binge Drinking and Alcohol Withdrawal on Serum Neurofilament Levels. PMID 42745461 — white matter, serum, binge drinking, poisoning, alcoholism, therapeutics, drinking, cognition | Addict Biol | 2026 | 0 |
| Delivering high-quality multiple sclerosis care in Germany: challenges and regional models. PMID 42706551 — sclerosis, multiple sclerosis, telemedicine, work, diagnosis, therapeutics, health services, digital health | Neurol Res Pract | 2026 | 0 |
| MSPEECH (multiple sclerosis monitoring through speech interaction in clinic and at home): a Living Lab study protocol for co-created, speech-based digital biomarkers in multiple sclerosis. PMID 42534930 — sclerosis, multiple sclerosis, workflow, biomarkers, artificial intelligence, speech, digital biomarkers | Front Digit Health | 2026 | 0 |
| [Neurofilament light chain as a tool for assessing disease activity and treatment response in Multiple Sclerosis]. PMID 42442405 — research design, sclerosis, multiple sclerosis, therapeutics, neurology, psychiatry | Fortschr Neurol Psychiatr | 2026 | 0 |
Clinical Studies 35
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
9 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing Remitting Multiple Sclerosis 2023-506516-40-00 — sclerosis, multiple sclerosis, safety, adolescent, multiple sclerosis, relapsing-remitting, child | Phase 3 | Active not recruiting | 2022 |
| A study to investigate long term safety and tolerability of tolebrutinib in participants with multiple sclerosis 2023-503631-18-01 — sclerosis, multiple sclerosis, safety, nervous system, nervous system diseases, primary progressive multiple sclerosis, secondary progressive multiple sclerosis | Phase 3 | Active not recruiting | 2024 |
| A Study to Investigate the Safety Tolerability Immunogenicity Pharmacokinetics and Pharmacodynamics of RO7121932 following Intravenous and Subcutaneous Administration in Participants with Multiple Sclerosis 2023-509357-31-00 — sclerosis, multiple sclerosis, safety, pharmacokinetics | Phase 1 | Recruiting | 2021 |
| A Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Participants with Multiple Sclerosis 2024-517980-22-00 — sclerosis, multiple sclerosis, therapeutic equivalency | Phase 2 | Active not recruiting | 2025 |
| A Rollover Study to Evaluate the Long Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis 2023-505974-14-00 — sclerosis, multiple sclerosis, safety | Phase 3 | Active not recruiting | 2022 |
LeadR Networks
Main global connection map